|
Dear
Dr. {{$doctorName}},
Subject: Evaluation of
Lipid levels and Associated Risk Markers in Indian dyslipidemia
Patients treated with Atorvastatin (LIPIMAP III) – A
retrospective, cross-sectional,
real world study
Dyslipidemia is the major condition responsible for the
atherosclerotic process, the
prevalence of dyslipidemia in Indians is very high with 79% of
subjects having at least
one lipid abnormality, with decreased high density lipoprotein
cholesterol (HDL-C) levels
in 72.3% subjects, hypertriglyceridemia in 29.5% subjects and
elevated low density
lipoprotein cholesterol (LDL-C) levels in 11.8% of subjects. Statins
remain main line of
treatment, with lifestyle modification. Intensified statin therapy
by increasing dose,
switching to a more potent statin or addition of Ezetimibe should be
considered to achieve
further reduction in LDL-C levels, and thereby prevention of ASCVD.
In India the prevalence of Ischemic Heart Disease is around 23.8
million, the prevalence
of Coronary artery Disease (CAD) is 21.4% for diabetics and 11% for
non-diabetics. The
prevalence of CAD in rural parts of country is nearly half than that
in urban population.
In secondary prevention cardiovascular disease (CVD), clinical
trials have demonstrated
that higher intensity levels of statin therapy are more effective
than lower levels in
reducing mortality rates. In post-MI cases, guideline compliant high
intensity statins &
adherence significantly lowers risk of MACE by 16% & adherence of
statins lowers
MACE by 7%.
Additionally, recent guideline statements have recommended
high-intensity statin therapy
(i.e., atorvastatin 80 mg or rosuvastatin 20-40 mg) for nearly all
patients who have
undergone cardiac intervention. For patients who cannot tolerate
high-dose statins and
those with contraindications, Ezetimibe may also be considered.
Risk factors like smoking, sedentary lifestyle, obesity,
hypertension and diabetes are all
important contributors to ASCVD. In The Dyslipidemia International
Study (DYSIS II)
hypertension and diabetes were identified as common risk factors
seen in patients with
coronary heart disease.
Currently there is limited evidence on prevalence of risk factors
like hypertension,
diabetes and obesity, as well as level of lipid control in Indian
patients with dyslipidemia.
Thus in lieu of the above, the present study is planned to evaluate
the prevalence of
ASCVD or ASCVD risk factors, level of lipid control and current
management practices
of dyslipidemia in Indian patients with or without ASCVD or ASCVD
risk factors.
We invite you to participate in this study. On acceptance, you will
need to capture the
relevant data as mentioned in the standard Data Collection Form
(DCF) provided, from
the patient’s medical records (case papers and investigational
reports – hereafter referred
as source documents).
We would recommend you to capture data fulfilling the criteria as
outlined in the protocol
and whose relevant laboratory investigations are available for the
preceding 3 months.
We wish to inform you that the DCF will capture all data in
de-identified form and any
identifiable parameters which may potentially disclose the identity
of the patient such as
name or address will strictly not be captured so as to ensure we
maintain patient
confidentiality. We would encourage you to carefully fill all
available information to the
fullest as recommended in the DCF.
|
}}){kind=logo}
}})